HYDAMTIQ, with the CAS number 1201832-32-7, is a chemical compound that has garnered attention in various fields, particularly in medicinal chemistry. It is characterized by its unique molecular structure, which contributes to its biological activity. Typically, compounds like HYDAMTIQ are evaluated for their potential therapeutic applications, often focusing on their efficacy, safety, and mechanism of action. The substance may exhibit specific solubility properties, stability under various conditions, and reactivity with other chemical entities, which are crucial for its application in drug development. Additionally, its pharmacokinetic and pharmacodynamic profiles are essential for understanding how it behaves in biological systems. As with many chemical substances, the characteristics of HYDAMTIQ would also include its synthesis methods, potential side effects, and regulatory status, which are important for researchers and developers in the pharmaceutical industry. Overall, HYDAMTIQ represents a compound of interest that may contribute to advancements in therapeutic strategies.

HYDAMTIQ

1201832-32-7: HYDAMTIQ, with the CAS number 1201832-32-7, is a chemical compound that has garnered attention in various fields, particularly in medicinal chemistry. It is characterized by its unique molecular structure, which contributes to its biological activity. Typically, compounds like HYDAMTIQ are evaluated for their potential therapeutic applications, often focusing on their efficacy, safety, and mechanism of action. The substance may exhibit specific solubility properties, stability under various conditions, and reactivity with other chemical entities, which are crucial for its application in drug development. Additionally, its pharmacokinetic and pharmacodynamic profiles are essential for understanding how it behaves in biological systems. As with many chemical substances, the characteristics of HYDAMTIQ would also include its synthesis methods, potential side effects, and regulatory status, which are important for researchers and developers in the pharmaceutical industry. Overall, HYDAMTIQ represents a compound of interest that may contribute to advancements in therapeutic strategies.

<p>HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].</p>

CAS 1201832-32-7

HYDAMTIQ

HYDAMTIQ

Ref: TM-T86694